Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion - PubMed (original) (raw)

Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion

J F Cajot et al. J Cell Biol. 1989 Aug.

Abstract

A cosmid (cos pUK0322) harboring the complete human urokinase-type plasminogen activator (u-PA) gene and Geneticin resistance as a selectable marker was isolated from a human genomic library and characterized. After transfection of cos pUK0322 into mouse L cells and selection, several plasminogen activator (PA)-expressing clones were obtained and one (LuPA) was chosen for additional study. The PA expressed was identical to human pro-u-PA in enzymatic, electrophoretic, and antigenic properties. The expression of PA was stable over 50 population doublings. The regulation of the transfected gene was studied by treatment of the cells with various hormones and other effectors. Expression of PA activity was inhibited fivefold by dexamethasone and stimulated two- to threefold by agonists of the adenylate cyclase dependent pathway of signal transduction, such as dibutyryl cyclic AMP and cholera and pertussis toxins. The modulation of PA activity was associated with corresponding changes in mRNA steady-state levels. The phenotypic changes associated with pro-u-PA expression were analyzed in vitro by degradation of 3H-labeled extracellular matrix (ECM), invasion of a matrigel basement membrane analogue, and by light and electron microscopy. LuPA cells and reference HT-1080 fibrosarcoma cells, in contrast to control Lneo cells transfected with the neomycin resistance gene, degraded the ECM and invaded the matrigel basement membrane. Matrix degradation correlated with the modulation of pro-u-PA gene expression as it was inhibited by dexamethasone and promoted by dibutyryl cyclic AMP. Inhibition of PA or plasmin using anti-u-PA IgG or aprotinin prevented ECM degradation and invasion. These results demonstrate that u-PA expression alone is sufficient to confer to a cell an experimental invasive phenotype.

PubMed Disclaimer

Similar articles

• Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor.
  Sordat B, Reiter L, Cajot JF. Sordat B, et al. Cell Differ Dev. 1990 Dec 2;32(3):277-85. doi: 10.1016/0922-3371(90)90040-4. Cell Differ Dev. 1990. PMID: 2129155 Review.
• Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
  Quax PH, Pedersen N, Masucci MT, Weening-Verhoeff EJ, Danø K, Verheijen JH, Blasi F. Quax PH, et al. Cell Regul. 1991 Oct;2(10):793-803. doi: 10.1091/mbc.2.10.793. Cell Regul. 1991. PMID: 1666303 Free PMC article.
• Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
  Cajot JF, Bamat J, Bergonzelli GE, Kruithof EK, Medcalf RL, Testuz J, Sordat B. Cajot JF, et al. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6939-43. doi: 10.1073/pnas.87.18.6939. Proc Natl Acad Sci U S A. 1990. PMID: 2169614 Free PMC article.

Cited by

• Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis.
  Kerbel RS, Cornil I, Theodorescu D. Kerbel RS, et al. Cancer Metastasis Rev. 1991 Oct;10(3):201-15. doi: 10.1007/BF00050792. Cancer Metastasis Rev. 1991. PMID: 1764765 Review.
• Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
  Quax PH, van Muijen GN, Weening-Verhoeff EJ, Lund LR, Danø K, Ruiter DJ, Verheijen JH. Quax PH, et al. J Cell Biol. 1991 Oct;115(1):191-9. doi: 10.1083/jcb.115.1.191. J Cell Biol. 1991. PMID: 1918136 Free PMC article.
• Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
  Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Lee KH, et al. Korean J Intern Med. 2006 Mar;21(1):20-7. doi: 10.3904/kjim.2006.21.1.20. Korean J Intern Med. 2006. PMID: 16646560 Free PMC article.
• The role of proteolytic enzymes in cancer invasion and metastasis.
  Duffy MJ. Duffy MJ. Clin Exp Metastasis. 1992 May;10(3):145-55. doi: 10.1007/BF00132746. Clin Exp Metastasis. 1992. PMID: 1582084 Review.
• Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
  Kunz C, Pebler S, Otte J, von der Ahe D. Kunz C, et al. Nucleic Acids Res. 1995 Sep 25;23(18):3710-7. doi: 10.1093/nar/23.18.3710. Nucleic Acids Res. 1995. PMID: 7479001 Free PMC article.

References

1. 1. Cell. 1983 Dec;35(3 Pt 2):611-9 - PubMed
2. 1. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1373-6 - PubMed
3. 1. J Biol Chem. 1986 Jun 15;261(17):7644-51 - PubMed
4. 1. J Cell Biol. 1987 May;104(5):1281-9 - PubMed
5. 1. Nucleic Acids Res. 1987 Oct 12;15(19):8118 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal